ID: ALA3604521

Max Phase: Preclinical

Molecular Formula: C20H15N5O4

Molecular Weight: 389.37

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=[N+]([O-])c1ccc2nc(Nc3ccc(O)cc3)c(Nc3ccc(O)cc3)nc2c1

Standard InChI:  InChI=1S/C20H15N5O4/c26-15-6-1-12(2-7-15)21-19-20(22-13-3-8-16(27)9-4-13)24-18-11-14(25(28)29)5-10-17(18)23-19/h1-11,26-27H,(H,21,23)(H,22,24)

Standard InChI Key:  RCUXUCBINZDYLY-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 389.37

Molecular Weight (Monoisotopic): 389.1124

AlogP: 4.44

#Rotatable Bonds: 5

Polar Surface Area: 133.44

Molecular Species: NEUTRAL

HBA: 8

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.88

CX Basic pKa: 0.95

CX LogP: 4.70

CX LogD: 4.70

Aromatic Rings: 4

Heavy Atoms: 29

QED Weighted: 0.22

Np Likeness Score: -0.91

References

1. Mota F, Gane P, Hampden-Smith K, Allerston CK, Garthwaite J, Selwood DL..  (2015)  A new small molecule inhibitor of soluble guanylate cyclase.,  23  (17): [PMID:26264842] [10.1016/j.bmc.2015.07.074]

2.  (2017)  Aryl amine substituted quinoxaline used as anticancer drugs, 

Source

Source(2):

• Scientific Literature
• Patent Bioactivity Data